There is a quiet decision inside every global launch plan that determines more economic value than any other single choice the team will make. It is rarely debated at the board level. It is almost never modelled with the rigour it deserves. And by the time its consequences are visible, they are irreversible.
It is the choice of first market.
The first market a therapy launches in does more than generate first revenue. It establishes the reference price, the comparator, the evidence package, and the negotiation posture that every subsequent market inherits. Reimbursement bodies in market three, market five, and market eight do not start from zero. They start from what market one accepted. Pricing chains, international reference pricing baskets, and HTA precedent quietly compound — for or against the asset — from the moment of first launch.
Most teams choose first market by size. The largest available market becomes the default, and the rest of the sequence is arranged around it. This is the wrong frame. Size matters for terminal value. It does not matter for what the first launch actually does, which is to set the terms of every negotiation that follows.
The decision is being actively re-engineered right now
The clearest contemporary illustration is Insmed and its rare respiratory therapy BRINSUPRI (brensocatib). FDA approval came on 12 August 2025 — the first and only approved treatment for non-cystic fibrosis bronchiectasis. European Commission approval followed on 18 November 2025. UK MHRA authorisation came on 20 February 2026. The asset is approved in three of the world's most important regulatory jurisdictions.
And as of mid-2026, Insmed has not launched commercially in Europe or the UK.
The company has stated, in successive earnings updates, that it "continues to evaluate the potential effect of evolving U.S. policies on the timing for future potential international commercial launches." On the Q1 2026 earnings call, CEO William Lewis said directly:
"It has caused us to pause our launch efforts in Europe and the UK … the prudent thing to do is to put things on hold until we know what that's going to look like."
The implication is that launching at European net prices while US pricing policy remains uncertain risks creating international price references the company may later struggle to defend.
Insmed is not alone. Reuters reported in March 2026 on a broader pattern of European launch deferrals across the industry. Stefan Oelrich, president of EFPIA — the European pharmaceutical trade body and senior Bayer executive — confirmed "first signs of delayed introductions into Europe" as companies recalibrate sequencing against US Most Favoured Nation pricing policy. GlobalData analysis cited in the same report found EU drug launches fell approximately 35% in the ten months following Trump's executive order, compared with the preceding ten months. This is no longer theoretical. Companies are paying real opportunity cost in European revenue to protect a US price they have not yet negotiated, because they understand — correctly — that the order in which they enter markets shapes the price chain for the life of the asset.
This is sequencing strategy being executed at scale, in real time, by listed companies, because the consequences of getting it wrong are now visible enough to override the default.
Three sequences, one asset
To see why the default deserves scrutiny even in calmer policy environments, consider a hypothetical rare disease therapy approaching pivotal data. Small patient population, strong mechanism, single-arm trial, anticipated annual price in the mid six figures. The board's instinct is US-first. Examine the same asset under three different first-market choices.
US-first.
FDA approval is achievable on the single-arm package. Commercial launch follows within months. List price is set high, consistent with US rare disease norms. The asset then enters European HTA. NICE in the UK, G-BA in Germany, HAS in France each evaluate the evidence on their own terms — and each one references, formally or informally, the US list price as an anchor for what the manufacturer believes the therapy is worth. The negotiation in every European market becomes a discount conversation from a number the payers consider unjustified by the comparative evidence. Net prices settle well below US list. Reference pricing baskets in Canada, Australia, and parts of Asia then re-anchor to the European nets. Terminal global net price is meaningfully lower than the headline US number ever suggested — and, in the current US policy environment, the European nets may now also pull the US price down via MFN logic.
UK-first.
NICE engagement begins pre-launch. The evidence package is built explicitly for HTA — comparator selection, quality-of-life endpoints, and budget impact modelling are designed against NICE methods from the start. A managed access agreement is negotiated, with confidential discount terms that preserve a defended public list price. This matters: confidential commercial agreements — Patient Access Schemes, managed access arrangements, and commercial access agreements — are essentially universal for NICE-recommended orphan and oncology treatments, functioning as the mechanism that allows manufacturers to maintain list price for the purposes of subsequent reference-priced markets while delivering an acceptable net price to NHS England.
The UK becomes a credible anchor for the rest of Europe, the Gulf, and Commonwealth markets that watch NICE closely. Germany and France enter with the NICE precedent on the table; the public list price holds; the negotiated nets do the commercial work. The Vertex experience with the cystic fibrosis franchise — a three-year standoff with NHS England that began with a £104,000–105,000 per patient ask against NICE's £20,000–30,000-per-QALY cost-effectiveness threshold — is the cautionary version of this strategy executed badly. The strategy works only when the evidence and the opening price are built for NICE methods from the start, not retrofitted to them.
Japan-first.
PMDA consultation begins early. The trial design accommodates Japanese regulatory expectations, including the data requirements that have historically caused drug lag in Japan. Approval and reimbursement listing occur in Japan ahead of the US, at a price set under Japan's Chuikyo system. The Central Social Insurance Medical Council uses a comparator-based pricing method for most drugs, with premiums available for innovation (now up to 70–120%), usefulness, orphan designation (5–20%), and Sakigake breakthrough designation for drugs first approved in Japan. In practice, for orphan drugs without a clear comparator, the cost accounting method can apply, which is generally the most favourable pricing mechanism.
The strategic value of Japan-first is not primarily the Japanese revenue, though it is meaningful. It is that Japan does not export pricing pressure to the US the way Europe now can. A Japan-first launch generates real-world evidence, builds clinical credibility, and produces revenue without creating a reference point that constrains US negotiation — provided Gulf exposure is managed separately.
These three sequences do not differ by execution quality. They differ by which market was chosen first. The asset is the same. The terminal economics are not.
Why the default is usually wrong
The US-first default persists for understandable reasons. US revenue is the largest single line in most launch models. US investors reward US progress. The FDA pathway is well-understood, and US commercial infrastructure is the most mature. None of this is wrong. It is simply incomplete.
What the default ignored, historically, was that the US was the only major market that did not reference-price internationally in a meaningful way. Every other market did — formally through reference pricing baskets, informally through HTA precedent, or commercially through tender comparisons. This asymmetry meant a US-first launch exported a price signal outward; the rest of the world then priced inward against that signal, discounted.
The MFN executive order has changed this calculation. For the first time in decades, the United States may no longer be reliably insulated from international reference pricing dynamics. The asymmetry that made US-first defensible for two decades is now contested. The Insmed pattern — approval secured, launch deferred — is the rational response from companies whose finance teams have run the numbers and concluded that committing to a European net price now is more expensive than waiting.
For boards that have not revisited their sequencing assumptions since 2024, the question is no longer whether US-first is theoretically optimal. It is whether the conditions that made it optimal still hold.
What changes when you sequence deliberately
A defensible first-market choice is built on four inputs, not one.
Market size is the first input most teams over-weight. The other three are usually under-weighted or skipped.
The second is comparator and evidence fit. Where does the existing evidence package perform best against the HTA methodology and competitive landscape? A package optimised for FDA may be weak against NICE; a package optimised against German comparators may underperform against US payers.
The third is spillover direction. Which markets reference this one? A launch in a market that anchors twelve other markets is a different decision from a launch in a market that anchors none. Under MFN, this question now includes the United States itself.
The fourth is what the launch infrastructure can actually deliver. A sequence is only as good as the team behind it. A theoretically optimal first market that the organisation cannot execute against is worse than a second-best market it can execute against well.
The decision is small. The consequences are not.
Choosing first market is a decision that often gets made in a single board meeting, frequently by analogy to whatever the last company did, and almost never with a sequencing model behind it. The cost of that under-investment shows up years later, in net prices that cannot be recovered, in HTA precedents that cannot be unwound, and in reference baskets that quietly compress the asset's global ceiling.
The companies pausing their European launches right now are doing the analysis that the rest of the market still treats as optional. The decision is small. The consequences are not.
If sequencing assumptions are changing, boards need a way to evaluate them deliberately rather than relying on precedent.
Cenvia's Sequencing Assessment is a fixed-fee engagement that gives boards a defensible answer to where to launch first, and why.